Category: Biotechnology & Life Sciences

Last month, Moderna’s stock jumped after its personalized mRNA melanoma vaccine with Merck won a Phase 3 trial. The market paid attention when Moderna announced late-stage trial results for its melanoma cancer vaccine. Their first patient got a dose of the vaccine in 2017, and it took about a decade to prove out. Here’s how…